Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of Lu AF95245 in Healthy Men
NCT04199585Phase 1Terminated
- Sponsor
- Lundbeck
- Start
- Dec 2019
- Primary completion
- Feb 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of Lu AF95245 in Neuropsychiatric disorders (3 cohorts), sponsored by Lundbeck. Primary endpoints: Treatment-emergent adverse events, Area Under the Curve (0-inf) and 3 more. Started Dec 2019; status: terminated.
02
Drugs
Lu AF95245
03
Conditions
Neuropsychiatric disorders
Beyond the preview
Go deeper on NCT04199585.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04199585.